Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL Fair value of deferred royalty obligation

Fair value of deferred royalty obligation at other companies

Ardelyx logo
ArdelyxARDX
$6.5M+1.4%
Ardelyx logo
ArdelyxARDX
$6.5M+1.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$11.29M+7,742%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$871.19M+75.2%
PTH
Pelthos TherapeuticsPTHS
$92.25K—
Omeros logo
OmerosOMER
$19.86M-5.8%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$1.16B+21.2%
Enterprise value$1.01B+23.0%
P/E24.2×-2.2×
P/S1.4×+0.1×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept coll:DeferredRoyaltyObligationFairValue.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851

The deferred royalty obligation is considered a Level 3 fair value measurement. The fair value of the Company’s deferred royalty obligation was approximately $142,617 as of June 30, 2026 and a net carrying value of $121,357.

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s fair value of deferred royalty obligation?
Collegium Pharmaceutical, Inc. (COLL) reported fair value of deferred royalty obligation of $142.62M in Q2 2026.
What does fair value of deferred royalty obligation mean?
Fair value of deferred royalty obligation as reported by Collegium Pharmaceutical, Inc. Common Stock.

Ask your AI about Collegium Pharmaceutical, Inc.'s fair value of deferred royalty obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude